Putting patients first is in uMotif’s DNA. The uMotif eCOA platform delivers faster, high-quality clinical trials and real-world studies by putting patients at the core of research. Combined with uMotif’s robust site tools — including consent management, site productivity, and trial awareness — the platform strengthens the patient-site relationship, which is key to improving eCOA compliance and retention.

The modern cloud-based platform enables a suite of real-time analytics, dashboards, and alerts to help sites and sponsors manage faster, more efficient trials. With cloud-hosting in the US, Europe, and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports all study phases and indications. Visit www.umotif.com 

With nearly 30 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology/toxicology (QSP/QST), and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, please visit https://www.simulations-plus.com/ 

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Direct-to-Patient Site and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit www.science37.com, or email science37@science37.com.

At Thermo Fisher Scientific, our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, or the development and manufacture of life-changing therapies, we are here to support. To learn more, visit thermofisher.com.

Covestro is one of the world's leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. For applications such as medication delivery, surgical instruments, electromedical equipment and wound care, Covestro offers dedicated thermoplastics, films, TPU, raw materials for adhesives, foams, and more. For more information, please visit https://solutions.covestro.com/en/industries/healthcare

SiCare Bio is enabling the next generation of nano-therapeutics through a novel drug delivery platform. Underpinning our platform are precision, nanoporous silicon dioxide particles, which we use to deliver extended and targeted-release therapies. For extended-release delivery, APIs are loaded into our nanoporous microparticles. Each particle is configured for a specific molecule and release profile. Our targeted-delivery system utilizes nano-sized nanoporous particles with high-loading efficiency to deliver payloads for direct cytosolic release.

Biotts S.A. is a pioneering biotechnology start-up based in Poland, dedicated to enhancing global health outcomes through innovative, needle-free transdermal drug delivery systems. Our cutting-edge technology aims to improve the quality of life for millions by enabling the delivery of large-molecule drugs such as insulin without the use of invasive procedures. For more information, please visit https://biotts.com/

Seaport-based Satio is radically improving the workflow of healthcare to allow it to decentralize while providing improved outcomes and broader, more equitable access. The two areas of focus are drug and vaccine delivery and on-board in vitro diagnostics. The origin of Satio and KKR Sapphiros traces to founder Namal Nawana, former CEO of Alere and of Smith & Nephew, who continues to pursue the passion he developed for decentralizing care of the highest quality prior to selling Alere to Abbott. https://satiopatch.com/news/

About Croda’s Pharma business – www.crodapharma.com Croda’s Pharma business is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid, delivery platforms.

Millstone Medical is a leading CDMO providing end-to-end solutions for combination device & drug packaging, assembly, testing and distribution. Founded in 2000 and headquartered in Massachusetts, Millstone Medical is your single source solution for clinical trials of combination products and speed to market. Our ISO 13485 dedicated class 7 clean rooms, innovative technology and skilled teams will guide your device from development to market. Our certified laboratories provide product, packaging and environmental testing to our biopharmaceutical customers 60% faster than industry norms. To learn more, please visit www.millstonemedical.com.

Ligandal delivers molecules precisely where they need to go. Using flexibly manufacturable, organ- and tissue-specific peptide ligands, their rapid and predictive, payload- and target-agnostic platform enables personalized, precision, and preventative medicine through delivery of nucleic acids, proteins, and molecular materials. Powered by LigandAI® and Predictive Interactomics®. For more information, visit https://api.ligandal.com/

ARx custom develops and manufactures transdermal patches and oral/transmucosal thin film delivery systems for unique drug delivery and patient needs. Our drug delivery technologies expand delivery possibilities for active pharmaceutical ingredients with tailored drug delivery profiles that meet the therapeutic needs of the patient with rapid onset or controlled release, all while enhancing compliance, bioavailability, and avoiding adverse events associated with the 1st pass metabolism. We partner to improve drug delivery at any stage in drug development, from product concept & feasibility assessment through commercial production.